/content/mofsl-website-adobe/fragments/open-demat-popup

style

hide-in-desktop

X T L Biopharmaceuticals Ltd share price today is $0.6463, up -3.06%. The stock opened at $0.648 against the previous close of $0.649899, with an intraday high of $0.6499 and low of $0.6364.

style

pb-0

X T L Biopharmaceuticals Ltd

/content/mofsl-website-adobe/demat-form-fields

style

sticky-block,pt-0

us-stock

style

pt-0

$0.6463 -0.0306(-3.06%) XTLB at 13 Mar 2026 03:58 PM Biotechnology

Lowest Today 0.6364

Highest Today 0.6499

Today’s Open 0.648

Prev. Close 0.649899

52 Week High 2.57

52 Week Low 0.53

Day’s Range: Low 0.6364 High 0.6499

52-Week Range: Low 0.53 High 2.57

X T L Biopharmaceuticals Ltd Institutional Holdings

X T L Biopharmaceuticals Ltd Market Status

X T L Biopharmaceuticals Ltd Fundamentals

Market Cap 6.15 M

PB Ratio 0.9722

PE Ratio 0.0

Enterprise Value 6.23 M

Total Assets 8.55 M

Volume 16902

X T L Biopharmaceuticals Ltd Company Financials

Annual Revenue FY23:0 0.0M, FY22:-459000 -0.5M, FY21:1466000 1.5M, FY20:28000 0.0M, FY19:69000 0.1M

Annual Profit FY23:null 0.0M, FY22:-459000 -0.5M, FY21:1466000 1.5M, FY20:28000 0.0M, FY19:69000 0.1M

Annual Net worth FY23:-2246000 -2.2M, FY22:-2309000 -2.3M, FY21:1901000 1.9M, FY20:-616000 -0.6M, FY19:-1278000 -1.3M

Quarterly Revenue Q1/2025:289000 0.3M, Q3/2024:162000 0.2M, Q2/2024:0 0.0M, Q1/2024:0 0.0M, Q4/2023:0 0.0M

Quarterly Profit Q1/2025:-43000 -0.0M, Q3/2024:162000 0.2M, Q2/2024:null 0.0M, Q1/2024:null 0.0M, Q4/2023:null 0.0M

Quarterly Net worth Q1/2025:-255000 -0.3M, Q3/2024:-553000 -0.6M, Q2/2024:-704000 -0.7M, Q1/2024:485000 0.5M, Q4/2023:-284000 -0.3M

About X T L Biopharmaceuticals Ltd & investment objective

Company Information XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. The company has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.

Organisation Biotechnology

Employees 10

Industry Biotechnology

CEO Mr. Noam Band

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*